Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management

Varvaresou, Athanasia; Iakovou, Kriton; Mellou, Fotini; Myrogiannis, Dimetrios; Papageorgiou, Spyros

doi:10.1111/jocd.13211

Cited by 9 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sumando a lo anterior, a partir de los resultados favorables en cuanto a la aceptación, tolerancia, evolución clínica y de la calidad de vida con los productos del kit, así como con otros dermocosméticos, se considera la posibilidad de un efecto sinérgico entre los productos de origen farmacológico y dermocosmético, los cuales en conjunto podrían impactar positivamente sobre los desenlaces clínicos. Aunque también, teniendo en cuenta la receptividad por parte de los pacientes y el buen desempeño de los dermocosméticos, el inicio de fármacos podría ser diferido para casos con un nivel de compromiso en piel moderado o severo, que no mejore con las medidas no farmacológicas 19,20,24,25 .…”

Section: Discussionunclassified

Aceptabilidad y tolerabilidad de un kit dermocosmético en pacientes en tratamiento oncológico con reacciones adversas dermatológicas

Contreras¹,

Sánchez-Vanegas²,

Ramírez³

et al. 2023

Rev.Col.Hematol.Oncol

View full text Add to dashboard Cite

Los eventos adversos cutáneos por antineoplásicos son frecuentes. En Colombia existe un kit dermocosmético, que restaura y protege la función de barrera de la piel. Objetivo: describir la experiencia de uso, evolución clínica y calidad de vida de pacientes con cáncer en tratamiento, a quienes se les prescribió un kit dermocosmético. Métodos: estudio observacional descriptivo basado en registros clínicos, incluyó pacientes con cáncer en tratamiento activo que recibieron un kit dermocosmético. De la consulta basal se tomaron datos sociodemográficos, nivel de xerosis, de funcionalidad y la escala Skindex-29. A las siete semanas se documentó la evolución clínica y la experiencia de uso del kit. Resultados: se incluyeron 59 pacientes con cáncer en tratamiento entre 25-89 años. De 0 a 10 recibieron una mediana de 10 puntos la facilidad de uso, la satisfacción global y la satisfacción por parte del médico. En el 91.5 % de los pacientes se redujo la xerosis; El prurito medido de 0 a 100, pasó de una mediana de 75 puntos al inicio del seguimiento a 25 puntos al final. La afectación severa de la calidad de vida pasó del 15.3 % de los pacientes en la medición basal al 5.1% luego de siete semanas de seguimiento. El dominio más afectado fue el de síntomas. Conclusiones: la facilidad de uso, la satisfacción global y la satisfacción por parte del médico con el kit dermocosmético fue excelente. Se produjo un efecto en la reducción de xerosis y prurito, y mejoró la calidad de vida de estos pacientes.

show abstract

Section: Discussionunclassified

Aceptabilidad y tolerabilidad de un kit dermocosmético en pacientes en tratamiento oncológico con reacciones adversas dermatológicas

Contreras¹,

Sánchez-Vanegas²,

Ramírez³

et al. 2023

Rev.Col.Hematol.Oncol

View full text Add to dashboard Cite

show abstract

“…Nevertheless, our finding that wound healing is impaired upon MEK inhibitor treatment and the fact that various MEK inhibitors are now widely used in cancer therapy have implications for the treatment of these patients. It should also be noted that skin adverse effects are highly common in cancer patients who received MEK inhibitor treatment ( Varvaresou et al., 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Single-cell RNA sequencing identifies a migratory keratinocyte subpopulation expressing THBS1 in epidermal wound healing

et al. 2022

View full text Add to dashboard Cite

“…The mean score for the medication literacy scale was recorded as 6.54 (SD = 2.78), which represented marginal literacy [ 4 – 10 ] in this study. Due to the lack of medication literacy assessment studies of cancer patients worldwide, it was not feasible to compare the medication literacy level of patients in a comparable population.…”

Section: Discussionmentioning

confidence: 99%

“…For this purpose, EGFR-positive NSCLC patients who received EGFR-TKI treatments were investigated in this study. Importantly, although there are various types of EGFR-TKIs clinically available, they have very similar mechanisms of reaction [ 10 ], which enabled the comparison and analysis of the data collected from patients using different types of EGFR-TKIs.…”

Section: Introductionmentioning

confidence: 99%

The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy

Yang

Zhou

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background High medication literacy is the basis of rational medication application and is essential for the management of severe adverse drug reactions. The objective of the present study was to assess the level of medication literacy and determine the association between medication literacy and skin adverse drug reactions in non-small-cell lung cancer (NSCLC) patients undergoing targeted epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy. Methods This is a cross-sectional study conducted from May to September 2020. In total, 296 NSCLC patients undergoing targeted EGFR-TKI therapy were recruited from hospitals in Henan, China. Structured questionnaires were used to evaluate skin adverse drug reactions and medication literacy. Pearson correlation analysis and binary logistic regression analysis were carried out to identify the correlations between medication literacy and the severity of skin adverse drug reactions in the recruited patients. Results The research sample consisted of 296 patients with a response rate of 92.5%. The mean score of skin adverse drug reactions and the mean score of medication literacy were 1.83 ± 0.91 and 6.54 ± 2.78, respectively. In total, 188 patients (63.5%) were considered to have moderate medication literacy. According to the binary logistic regression analysis, the following factors were associated with severe skin adverse drug reactions: age (B = − 3.929, P = 0.000), sex (B = -4.062, P = 0.000), educational level (B = 2.712, P = 0.002), comorbidity (B = 3.297, P = 0.001), eczema history (B = 2.996, P = 0.001), nutritional status (B = -4.891, P = 0.000), blood interleukin-6 level (B = -2.143, P = 0.013), blood high-sensitivity C-reactive protein level (B = -4.015, P = 0.000), combination of drugs (B = -3.183, P = 0.048) and medication literacy (B = − 1.503, P = 0.000). Subgroup analysis showed that in addition to medication literacy, some other factors including education level, comorbidity, nutritional status, blood interleukin-6 level and combined drug application were common factors that contributed to various adverse skin drug reactions in NSCLC patients under targeted EGFR-TKI therapy. Conclusion The low medication literacy of the investigated NSCLC patients undergoing targeted EGFR-TKI therapy was correlated with a high proportion of severe skin adverse drug reactions. In addition, factors other than medication literacy including education level, comorbidity, nutritional status, blood interleukin-6 level and the combinatorial application of drugs were also related to the severity of various adverse skin drug reactions. A comprehensive and targeted intervention may be beneficial to improve medication literacy and control severe skin adverse drug reactions in NSCLC patients.

show abstract

Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management

Cited by 9 publications

References 51 publications

Aceptabilidad y tolerabilidad de un kit dermocosmético en pacientes en tratamiento oncológico con reacciones adversas dermatológicas

Aceptabilidad y tolerabilidad de un kit dermocosmético en pacientes en tratamiento oncológico con reacciones adversas dermatológicas

Single-cell RNA sequencing identifies a migratory keratinocyte subpopulation expressing THBS1 in epidermal wound healing

The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy

Contact Info

Product

Resources

About